Literature DB >> 33425682

Post COVID-19 fibrosis, an emerging complicationof SARS-CoV-2 infection.

Mousa Ahmad Alhiyari1, Fateen Ata1, Mohd Islam Alghizzawi1, Ammara Bint I Bilal2, Ahmad Salih Abdulhadi1, Zohaib Yousaf1.   

Abstract

SARS-COV-2 has created one of the most massive pandemics in modern history. There is a rapid accumulation of data on its epidemiology, clinical course, diagnosis, management, and complications. One of the sequelae of COVID-19 pneumonia and acute respiratory distress syndrome (ARDS) is pulmonary fibrosis. There is a dearth of accurate data on the prevalence of pulmonary fibrosis post-COVID-19. We report a patient who developed dyspnea secondary to pulmonary fibrosis after successful treatment of COVID-19 pneumonia.
© 2020 The Authors.

Entities:  

Keywords:  ARDS; Acute respiratory distress syndrome; COVID-19; Coronavirus infection 2019; Dyspnea; Pulmonary fibrosis; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2

Year:  2020        PMID： 33425682      PMCID： PMC7785952          DOI： 10.1016/j.idcr.2020.e01041

Source DB:  PubMed          Journal:  IDCases        ISSN： 2214-2509


  16 in total

Review 1.  Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment.

Authors:  P J Sime; K M O'Reilly
Journal:  Clin Immunol       Date:  2001-06       Impact factor: 3.969

Review 2.  Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature.

Authors:  Luba Nalysnyk; Javier Cid-Ruzafa; Philip Rotella; Dirk Esser
Journal:  Eur Respir Rev       Date:  2012-12-01

Review 3.  COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection.

Authors:  Kacper Lechowicz; Sylwester Drożdżal; Filip Machaj; Jakub Rosik; Bartosz Szostak; Małgorzata Zegan-Barańska; Jowita Biernawska; Wojciech Dabrowski; Iwona Rotter; Katarzyna Kotfis
Journal:  J Clin Med       Date:  2020-06-19       Impact factor: 4.241

4.  Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.

Authors:  Xintian Xu; Ping Chen; Jingfang Wang; Jiannan Feng; Hui Zhou; Xuan Li; Wu Zhong; Pei Hao
Journal:  Sci China Life Sci       Date:  2020-01-21       Impact factor: 6.038

Review 5.  Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.

Authors:  Peter M George; Athol U Wells; R Gisli Jenkins
Journal:  Lancet Respir Med       Date:  2020-05-15       Impact factor: 30.700

6.  Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.

Authors:  Xiaoneng Mo; Wenhua Jian; Zhuquan Su; Mu Chen; Hui Peng; Ping Peng; Chunliang Lei; Ruchong Chen; Nanshan Zhong; Shiyue Li
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

Review 7.  What we know so far: COVID-19 current clinical knowledge and research.

Authors:  Mary A Lake
Journal:  Clin Med (Lond)       Date:  2020-03-05       Impact factor: 2.659

8.  COVID-19 presenting with diarrhoea and hyponatraemia.

Authors:  Fateen Ata; Hussam Almasri; Jamal Sajid; Zohaib Yousaf
Journal:  BMJ Case Rep       Date:  2020-06-07

9.  Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients.

Authors:  Kai Liu; Ying Chen; Ruzheng Lin; Kunyuan Han
Journal:  J Infect       Date:  2020-03-27       Impact factor: 6.072
View more
  12 in total

1.  Spontaneous tension pneumothorax as a complication of Coronavirus disease 2019: Case report and literature review.

Authors:  Fateen Ata; Zohaib Yousaf; Rana Farsakoury; Adeel Ahmad Khan; Abdullah Arshad; Maya Omran; Dore Chikkahanasoge Ananthegowda; Mohamad Khatib; Talat Saeed Chughtai
Journal:  Clin Case Rep       Date:  2022-05-09

2.  Baseline Plasma Gas6 Protein Elevation Predicts Adverse Outcomes in Hospitalized COVID-19 Patients.

Authors:  Stelvio Tonello; Manuela Rizzi; Erica Matino; Martina Costanzo; Giuseppe Francesco Casciaro; Alessandro Croce; Eleonora Rizzi; Erika Zecca; Anita Pedrinelli; Veronica Vassia; Raffaella Landi; Mattia Bellan; Luigi Mario Castello; Rosalba Minisini; Venkata Ramana Mallela; Davide D'Onghia; Gian Carlo Avanzi; Mario Pirisi; Daniele Lilleri; Pier Paolo Sainaghi
Journal:  Dis Markers       Date:  2022-04-29       Impact factor: 3.464

Review 3.  Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)-A Systemic Review and Comparison of Clinical Presentation and Symptomatology.

Authors:  Timothy L Wong; Danielle J Weitzer
Journal:  Medicina (Kaunas)       Date:  2021-04-26       Impact factor: 2.430

Review 4.  Emerging drug delivery strategies for idiopathic pulmonary fibrosis treatment.

Authors:  Moez Ghumman; Dinesh Dhamecha; Andrea Gonsalves; Lauren Fortier; Parand Sorkhdini; Yang Zhou; Jyothi U Menon
Journal:  Eur J Pharm Biopharm       Date:  2021-04-18       Impact factor: 5.589

5.  Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.

Authors:  Katarzyna Kotfis; Igor Karolak; Kacper Lechowicz; Małgorzata Zegan-Barańska; Agnieszka Pikulska; Paulina Niedźwiedzka-Rystwej; Miłosz Kawa; Jerzy Sieńko; Aleksandra Szylińska; Magda Wiśniewska
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-05

Review 6.  Covid-19 sequelae in working age patients: A systematic review.

Authors:  Gabriele d'Ettorre; Elio Gentilini Cacciola; Letizia Santinelli; Gabriella De Girolamo; Ornella Spagnolello; Alessandro Russo; Lorenzo Tarsitani; Massimo Ciccozzi; Claudio M Mastroianni; Gabriella d'Ettorre; Giancarlo Ceccarelli
Journal:  J Med Virol       Date:  2021-10-22       Impact factor: 20.693

7.  Comparison of pirfenidone and corticosteroid treatments at the COVID-19 pneumonia with the guide of artificial intelligence supported thoracic computed tomography.

Authors:  Murat Acat; Pinar Yildiz Gulhan; Serkan Oner; Muhammed Kamil Turan
Journal:  Int J Clin Pract       Date:  2021-10-17       Impact factor: 3.149

8.  Exophilone, a Tetrahydrocarbazol-1-one Analogue with Anti-Pulmonary Fibrosis Activity from the Deep-Sea Fungus Exophiala oligosperma MCCC 3A01264.

Authors:  Ming-Jun Hong; Meng-Jiao Hao; Guang-Yu Zhang; Hou-Jin Li; Zong-Ze Shao; Xiu-Pian Liu; Wen-Zhe Ma; Jun Xu; Taifo Mahmud; Wen-Jian Lan
Journal:  Mar Drugs       Date:  2022-07-09       Impact factor: 6.085

9.  A deep-learning based multimodal system for Covid-19 diagnosis using breathing sounds and chest X-ray images.

Authors:  Unais Sait; Gokul Lal K V; Sanjana Shivakumar; Tarun Kumar; Rahul Bhaumik; Sunny Prajapati; Kriti Bhalla; Anaghaa Chakrapani
Journal:  Appl Soft Comput       Date:  2021-05-26       Impact factor: 6.725

10.  The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on "Profibrotic Cytokine" IL-1β Levels in Severe and Critical COVID-19 Patients: A Preliminary Study.

Authors:  Karina Karina; Louis Martin Christoffel; Rita Novariani; Imam Rosadi; Iis Rosliana; Siti Rosidah; Siti Sobariah; Novy Fatkhurohman; Nurlaela Puspitaningrum; Yuli Hertati; Irsyah Afini; Difky Ernanda; Tias Widyastuti; A D Sulaeha; Alfida Zakiyah; Noor Aini; Grady Krisandi; Hubert Andrew
Journal:  Scientifica (Cairo)       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.